Overcoming barriers to cancer clinical trial accrual

BACKGROUND. Annually, only 3% of adult patients participate in cancer clinical trials (CCT). Accrual barriers include lack of CCT awareness and uncertain third‐party coverage. In 2002, a California law (SB37) required all insurers to reimburse costs related to CCT. The objective of the current study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2008-01, Vol.112 (1), p.212-219
Hauptverfasser: Umutyan, Ari, Chiechi, Christine, Beckett, Laurel A., Paterniti, Debora A., Turrell, Corinne, Gandara, David R., Davis, Sharon W., Wun, Ted, Chen, Moon S., Lara, Primo N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 219
container_issue 1
container_start_page 212
container_title Cancer
container_volume 112
creator Umutyan, Ari
Chiechi, Christine
Beckett, Laurel A.
Paterniti, Debora A.
Turrell, Corinne
Gandara, David R.
Davis, Sharon W.
Wun, Ted
Chen, Moon S.
Lara, Primo N.
description BACKGROUND. Annually, only 3% of adult patients participate in cancer clinical trials (CCT). Accrual barriers include lack of CCT awareness and uncertain third‐party coverage. In 2002, a California law (SB37) required all insurers to reimburse costs related to CCT. The objective of the current study was to increase awareness of CCT and SB37 through a mass multimedia campaign (MMC) in the University of California (UC) Davis (UCD) Cancer Center catchment area. The authors assessed willingness to participate in and accrual to CCT. METHODS. Changes in CCT/SB37 awareness and willingness to participate were investigated before the MMC versus after the MMC and in UCD respondents versus UC San Diego (UCSD) catchment respondents—a control group that was not exposed to the MMC—by Pearson chi‐square and logistic regression analyses. RESULTS. Of 1081 post‐MMC respondents, 957 were from UCD, and 124 from UCSD. UCD respondents had a greater awareness of CCT (59% vs 65%; P < .01) and SB37 (17% vs 32%; P < .01) compared with UCSD respondents. Willingness to participate did not change in either cohort. Awareness level predicted willingness (odds ratio, 2.3; P < .01). Blacks, Asians, and lowest income (
doi_str_mv 10.1002/cncr.23170
format Article
fullrecord <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_primary_10_1002_cncr_23170_CNCR23170</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CNCR23170</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1190-9aca7fae84fa142999157e943875de65ca0bc2ce6d520d90e500ec758fe3bede3</originalsourceid><addsrcrecordid>eNotj81KAzEUhYMoOFY3PkFeYOpNMmkmSxn8KRQLouAu3LlzRyLpVDJV6ds7rW7Oz-ZwPiGuFcwVgL6hgfJcG-XgRBQKvCtBVfpUFABQl7Yyb-fiYhw_puq0NYWo1t-cabuJw7tsMefIeZS7rSQciLOkFIdImOQux0mRKH9huhRnPaaRr_59Jl7v716ax3K1flg2t6uSlPJQeiR0PXJd9Ti98N4r69hXpna244UlhJY08aKzGjoPbAGYnK17Ni13bGZC_e3-xMT78JnjBvM-KAgH2HCADUfY0Dw1z8dkfgFydUp2</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Overcoming barriers to cancer clinical trial accrual</title><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Umutyan, Ari ; Chiechi, Christine ; Beckett, Laurel A. ; Paterniti, Debora A. ; Turrell, Corinne ; Gandara, David R. ; Davis, Sharon W. ; Wun, Ted ; Chen, Moon S. ; Lara, Primo N.</creator><creatorcontrib>Umutyan, Ari ; Chiechi, Christine ; Beckett, Laurel A. ; Paterniti, Debora A. ; Turrell, Corinne ; Gandara, David R. ; Davis, Sharon W. ; Wun, Ted ; Chen, Moon S. ; Lara, Primo N.</creatorcontrib><description><![CDATA[BACKGROUND. Annually, only 3% of adult patients participate in cancer clinical trials (CCT). Accrual barriers include lack of CCT awareness and uncertain third‐party coverage. In 2002, a California law (SB37) required all insurers to reimburse costs related to CCT. The objective of the current study was to increase awareness of CCT and SB37 through a mass multimedia campaign (MMC) in the University of California (UC) Davis (UCD) Cancer Center catchment area. The authors assessed willingness to participate in and accrual to CCT. METHODS. Changes in CCT/SB37 awareness and willingness to participate were investigated before the MMC versus after the MMC and in UCD respondents versus UC San Diego (UCSD) catchment respondents—a control group that was not exposed to the MMC—by Pearson chi‐square and logistic regression analyses. RESULTS. Of 1081 post‐MMC respondents, 957 were from UCD, and 124 from UCSD. UCD respondents had a greater awareness of CCT (59% vs 65%; P < .01) and SB37 (17% vs 32%; P < .01) compared with UCSD respondents. Willingness to participate did not change in either cohort. Awareness level predicted willingness (odds ratio, 2.3; P < .01). Blacks, Asians, and lowest income (<$25 K per year) groups were the least willing to participate (P < .01, P < .04, and P < .02, respectively). The CCT accrual rate at UCD was unchanged. CONCLUSIONS. CCT and SB37 awareness increased significantly in the UCD cohort after the MMC. However, it was unclear whether this increase was attributable entirely to the MMC or to varying demographic variables. Enhancing patient willingness and accrual will require targeting other variables, such as physician or resource barriers, rather than just CCT and reimbursement awareness. Cancer 2008. © 2007 American Cancer Society. The authors sought to increase awareness of cancer clinical trials (CCT) and of a new law that required all insurers to reimburse costs related to CCT through a mass multimedia campaign (MMC) in the catchment area of the University of California Davis Cancer Center. They assessed willingness to participate in and accrual to CCT. The results indicated that awareness increased significantly after the MMC, although it was unclear whether the increase was attributable entirely to the MMC or to varying demographic variables.]]></description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.23170</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>accrual rate ; barriers to participation ; California Law SB37 ; cancer clinical trials</subject><ispartof>Cancer, 2008-01, Vol.112 (1), p.212-219</ispartof><rights>Copyright © 2007 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1190-9aca7fae84fa142999157e943875de65ca0bc2ce6d520d90e500ec758fe3bede3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.23170$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.23170$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,1434,27929,27930,45579,45580,46414,46838</link.rule.ids></links><search><creatorcontrib>Umutyan, Ari</creatorcontrib><creatorcontrib>Chiechi, Christine</creatorcontrib><creatorcontrib>Beckett, Laurel A.</creatorcontrib><creatorcontrib>Paterniti, Debora A.</creatorcontrib><creatorcontrib>Turrell, Corinne</creatorcontrib><creatorcontrib>Gandara, David R.</creatorcontrib><creatorcontrib>Davis, Sharon W.</creatorcontrib><creatorcontrib>Wun, Ted</creatorcontrib><creatorcontrib>Chen, Moon S.</creatorcontrib><creatorcontrib>Lara, Primo N.</creatorcontrib><title>Overcoming barriers to cancer clinical trial accrual</title><title>Cancer</title><description><![CDATA[BACKGROUND. Annually, only 3% of adult patients participate in cancer clinical trials (CCT). Accrual barriers include lack of CCT awareness and uncertain third‐party coverage. In 2002, a California law (SB37) required all insurers to reimburse costs related to CCT. The objective of the current study was to increase awareness of CCT and SB37 through a mass multimedia campaign (MMC) in the University of California (UC) Davis (UCD) Cancer Center catchment area. The authors assessed willingness to participate in and accrual to CCT. METHODS. Changes in CCT/SB37 awareness and willingness to participate were investigated before the MMC versus after the MMC and in UCD respondents versus UC San Diego (UCSD) catchment respondents—a control group that was not exposed to the MMC—by Pearson chi‐square and logistic regression analyses. RESULTS. Of 1081 post‐MMC respondents, 957 were from UCD, and 124 from UCSD. UCD respondents had a greater awareness of CCT (59% vs 65%; P < .01) and SB37 (17% vs 32%; P < .01) compared with UCSD respondents. Willingness to participate did not change in either cohort. Awareness level predicted willingness (odds ratio, 2.3; P < .01). Blacks, Asians, and lowest income (<$25 K per year) groups were the least willing to participate (P < .01, P < .04, and P < .02, respectively). The CCT accrual rate at UCD was unchanged. CONCLUSIONS. CCT and SB37 awareness increased significantly in the UCD cohort after the MMC. However, it was unclear whether this increase was attributable entirely to the MMC or to varying demographic variables. Enhancing patient willingness and accrual will require targeting other variables, such as physician or resource barriers, rather than just CCT and reimbursement awareness. Cancer 2008. © 2007 American Cancer Society. The authors sought to increase awareness of cancer clinical trials (CCT) and of a new law that required all insurers to reimburse costs related to CCT through a mass multimedia campaign (MMC) in the catchment area of the University of California Davis Cancer Center. They assessed willingness to participate in and accrual to CCT. The results indicated that awareness increased significantly after the MMC, although it was unclear whether the increase was attributable entirely to the MMC or to varying demographic variables.]]></description><subject>accrual rate</subject><subject>barriers to participation</subject><subject>California Law SB37</subject><subject>cancer clinical trials</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotj81KAzEUhYMoOFY3PkFeYOpNMmkmSxn8KRQLouAu3LlzRyLpVDJV6ds7rW7Oz-ZwPiGuFcwVgL6hgfJcG-XgRBQKvCtBVfpUFABQl7Yyb-fiYhw_puq0NYWo1t-cabuJw7tsMefIeZS7rSQciLOkFIdImOQux0mRKH9huhRnPaaRr_59Jl7v716ax3K1flg2t6uSlPJQeiR0PXJd9Ti98N4r69hXpna244UlhJY08aKzGjoPbAGYnK17Ni13bGZC_e3-xMT78JnjBvM-KAgH2HCADUfY0Dw1z8dkfgFydUp2</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Umutyan, Ari</creator><creator>Chiechi, Christine</creator><creator>Beckett, Laurel A.</creator><creator>Paterniti, Debora A.</creator><creator>Turrell, Corinne</creator><creator>Gandara, David R.</creator><creator>Davis, Sharon W.</creator><creator>Wun, Ted</creator><creator>Chen, Moon S.</creator><creator>Lara, Primo N.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope/></search><sort><creationdate>20080101</creationdate><title>Overcoming barriers to cancer clinical trial accrual</title><author>Umutyan, Ari ; Chiechi, Christine ; Beckett, Laurel A. ; Paterniti, Debora A. ; Turrell, Corinne ; Gandara, David R. ; Davis, Sharon W. ; Wun, Ted ; Chen, Moon S. ; Lara, Primo N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1190-9aca7fae84fa142999157e943875de65ca0bc2ce6d520d90e500ec758fe3bede3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>accrual rate</topic><topic>barriers to participation</topic><topic>California Law SB37</topic><topic>cancer clinical trials</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Umutyan, Ari</creatorcontrib><creatorcontrib>Chiechi, Christine</creatorcontrib><creatorcontrib>Beckett, Laurel A.</creatorcontrib><creatorcontrib>Paterniti, Debora A.</creatorcontrib><creatorcontrib>Turrell, Corinne</creatorcontrib><creatorcontrib>Gandara, David R.</creatorcontrib><creatorcontrib>Davis, Sharon W.</creatorcontrib><creatorcontrib>Wun, Ted</creatorcontrib><creatorcontrib>Chen, Moon S.</creatorcontrib><creatorcontrib>Lara, Primo N.</creatorcontrib><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Umutyan, Ari</au><au>Chiechi, Christine</au><au>Beckett, Laurel A.</au><au>Paterniti, Debora A.</au><au>Turrell, Corinne</au><au>Gandara, David R.</au><au>Davis, Sharon W.</au><au>Wun, Ted</au><au>Chen, Moon S.</au><au>Lara, Primo N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overcoming barriers to cancer clinical trial accrual</atitle><jtitle>Cancer</jtitle><date>2008-01-01</date><risdate>2008</risdate><volume>112</volume><issue>1</issue><spage>212</spage><epage>219</epage><pages>212-219</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract><![CDATA[BACKGROUND. Annually, only 3% of adult patients participate in cancer clinical trials (CCT). Accrual barriers include lack of CCT awareness and uncertain third‐party coverage. In 2002, a California law (SB37) required all insurers to reimburse costs related to CCT. The objective of the current study was to increase awareness of CCT and SB37 through a mass multimedia campaign (MMC) in the University of California (UC) Davis (UCD) Cancer Center catchment area. The authors assessed willingness to participate in and accrual to CCT. METHODS. Changes in CCT/SB37 awareness and willingness to participate were investigated before the MMC versus after the MMC and in UCD respondents versus UC San Diego (UCSD) catchment respondents—a control group that was not exposed to the MMC—by Pearson chi‐square and logistic regression analyses. RESULTS. Of 1081 post‐MMC respondents, 957 were from UCD, and 124 from UCSD. UCD respondents had a greater awareness of CCT (59% vs 65%; P < .01) and SB37 (17% vs 32%; P < .01) compared with UCSD respondents. Willingness to participate did not change in either cohort. Awareness level predicted willingness (odds ratio, 2.3; P < .01). Blacks, Asians, and lowest income (<$25 K per year) groups were the least willing to participate (P < .01, P < .04, and P < .02, respectively). The CCT accrual rate at UCD was unchanged. CONCLUSIONS. CCT and SB37 awareness increased significantly in the UCD cohort after the MMC. However, it was unclear whether this increase was attributable entirely to the MMC or to varying demographic variables. Enhancing patient willingness and accrual will require targeting other variables, such as physician or resource barriers, rather than just CCT and reimbursement awareness. Cancer 2008. © 2007 American Cancer Society. The authors sought to increase awareness of cancer clinical trials (CCT) and of a new law that required all insurers to reimburse costs related to CCT through a mass multimedia campaign (MMC) in the catchment area of the University of California Davis Cancer Center. They assessed willingness to participate in and accrual to CCT. The results indicated that awareness increased significantly after the MMC, although it was unclear whether the increase was attributable entirely to the MMC or to varying demographic variables.]]></abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><doi>10.1002/cncr.23170</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2008-01, Vol.112 (1), p.212-219
issn 0008-543X
1097-0142
language eng
recordid cdi_wiley_primary_10_1002_cncr_23170_CNCR23170
source Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection
subjects accrual rate
barriers to participation
California Law SB37
cancer clinical trials
title Overcoming barriers to cancer clinical trial accrual
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T17%3A09%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overcoming%20barriers%20to%20cancer%20clinical%20trial%20accrual&rft.jtitle=Cancer&rft.au=Umutyan,%20Ari&rft.date=2008-01-01&rft.volume=112&rft.issue=1&rft.spage=212&rft.epage=219&rft.pages=212-219&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.23170&rft_dat=%3Cwiley%3ECNCR23170%3C/wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true